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Abstract
Background In ENSURE-AF study, edoxaban had similar efficacy and safety profile versus enoxaparin–warfarin (enox–warf) 
in patients undergoing electrical cardioversion of non-valvular atrial fibrillation.
Objectives To evaluate the efficacy and safety of edoxaban versus enox–warf in patients who were vitamin K antagonists 
(VKA) naïve or experienced at time of randomisation into ENSURE-AF trial.
Methods The primary efficacy endpoint was a composite of stroke, systemic embolic event, myocardial infarction, and 
cardiovascular death during the overall study period, 28 days on study drug after cardioversion and 30 days follow-up. The 
primary safety endpoint was the composite of major and clinically relevant nonmajor bleeding during the on-medication 
period from time of first dose to last dose of study drug taken + 3 days.
Results Of 2199 patients enrolled in ENSURE-AF, 1095 were randomised to edoxaban and 1104 to enox–warf. There were 
numerically fewer primary efficacy endpoint events with edoxaban than enox–warf irrespective of whether VKA experienced 
or naïve (0.5% vs. 0.9%, 0.3% vs. 1.4%, respectively). There were no significant differences in the primary safety endpoint 
[odds ratio (OR) 2.09, 95% confidence interval (CI) 0.72–6.81 in anticoagulant experienced patients, OR 0.77, 95% CI 
0.15–3.60 in anticoagulant naïve patients] and in major bleeding rates regardless of treatment or VKA experience (OR 0.69, 
95%CI 0.06–6.04, OR 0.48, 95% CI 0.01–9.25, respectively).
Conclusions Edoxaban had comparable efficacy and safety to optimized anticoagulation with enox–warf. The primary effi-
cacy and safety endpoint outcomes were broadly similar between VKA experienced or naïve patients.
Keywords Atrial fibrillation · Edoxaban · Vitamin K antagonists
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Introduction
Stroke prevention with oral anticoagulation (OAC) is one 
of the cornerstones of atrial fibrillation (AF) management 
[1]. Moreover, non-vitamin K antagonist oral anticoagu-
lants (NOACs) are increasingly recommended as first line 
management for stroke prevention in AF [2, 3]. Studies 
assessing NOACs show that they cause less intracranial 
haemorrhage and life-threatening bleedings when com-
pared to warfarin, as well as a reduction in mortality [4].
OAC significantly reduces stroke in patients undergo-
ing electrical cardioversion (ECV) [5, 6]. Initiation of 
OAC is obligatory in all patients planned for cardiover-
sion [7, 8], and permanent OAC continuation after ECV 
is indicated in all subjects with stroke risk factors based 
on  CHA2DS2-VASc score (congestive heart failure, hyper-
tension, age ≥ 75 years, diabetes, stroke/transient ischae-
mic attack (TIA), vascular disease, age 65–74 years, sex 
category) [2, 3]. In case of early ECV, transesophageal 
echocardiography (TEE) may be useful for excluding the 
majority of left atrial thrombi.
The Edoxaban versus warfarin in subjects undergoing 
cardioversion of atrial fibrillation (ENSURE-AF) assessed 
the use of edoxaban vs. enoxaparin–warfarin in patients 
with non-valvular AF undergoing ECV [9]. This large pro-
spective, randomised, multicenter open-label trial showed 
a similar efficacy and safety profile of edoxaban vs. enoxa-
parin–warfarin (enox–warf) in patients with non-valvular 
AF. Whether this is related to prior vitamin K antagonist 
(VKA) exposure or not is uncertain.
The aim of this ancillary analysis from the ENSURE-
AF trial was to evaluate the efficacy and safety of edoxa-
ban vs. enox–warf in patients who were VKA naïve or 
experienced at the time of randomisation in the ENSURE-
AF study.
Methods
The design of the ENSURE-AF trial (NCT 02,072,434) 
has been previously reported [9, 10]. In brief, this study 
is a multicentre, prospective, randomised, open-label 
(patients, statisticians and investigators were not masked 
to treatment allocation) trial with blinded endpoint assess-
ment. The patients with non-valvular AF (lasting from 48 h 
to 12 months), eligible for ECV and OAC were enrolled. 
The patients’ stratification was based on cardioversion 
approach (TEE or non-TEE), as established by the local 
investigator or determined by the patient’s previous experi-
ence with OAC (i.e. VKA experience vs. naive), edoxaban 
dose and region. Edoxaban 60 mg once daily (QD; 30 mg 
QD for creatinine clearance [CrCl] of 15–50 mL/min, 
weight ≤ 60 kg, and/or concomitant use of P-glycoprotein 
inhibitor) was compared with enoxaparin–warfarin in 
2199 patients (randomisation 1:1; Fig. 1). Subjects with 
an international normalised ratio (INR) < 2.0 at randomi-
sation were treated with enoxaparin bridging and daily 
warfarin until the INR was ≥ 2.0, and those with INR ≥ 2.0 
at the time of randomisation did not need enoxaparin and 
were medicated with warfarin alone. The dosing of war-
farin was adjusted to achieve and maintain the INR level 
from 2.0 to 3.0. INR was assessed once every 2–3 days 
until the value achieved the therapeutic range. Subjects in 
edoxaban group had to start medication at least 2 h prior 
ECV. The next dose of edoxaban was taken next day and 
then on a 24-h cycle until day 28 post cardioversion.
In the TEE-guided group, TEE and ECV had to be done 
within 3 days of randomisation. In case of presence of 
thrombi on TEE, patients had a possibility of completing 
28 days of study medication without ECV or being discon-
tinued from the study.
In all patients, ECV was done at a minimum of 21 days 
following the start of medication. In the edoxaban group, 
patients were treated with edoxaban for a minimum of 
21 days before cardioversion followed by the procedure 
and an additional 28 days of treatment. An algorithm 
dedicated to the treatment of patients with labile INR 
was included in the protocol and the 21-day pre-treatment 
cycle was possible to be restarted under predefined cir-
cumstances. The patients who were relocated from a previ-
ous OAC to edoxaban did so in accordance with the tran-
sition algorithm provided. The patients with spontaneous 
cardioversion in the preprocedural period (confirmed by 
a recording of sinus rhythm in electrocardiogram) were 
required to complete 28 days of treatment from the day 
that spontaneous cardioversion was recorded and 30 days 
of follow-up.
The study protocol is concordant with the Declaration 
of Helsinki and the International Conference on Harmoni-
zation consolidated guideline E6 for Good Clinical Prac-
tice (CPMP/ICH/135/95). A signed patient informed con-
sent form was acquired before participation in the study.
The primary efficacy endpoint was defined as a compos-
ite of stroke, systemic embolic event (SEE), myocardial 
infarction (MI), and cardiovascular death analysed during 
the overall study period, 28 days on study drug after car-
dioversion and then follow-up was performed for safety 
for another 30 days after completing or discontinuing the 
medication. The primary safety endpoint was the com-
posite of major and clinically relevant nonmajor bleeding 
(CRNM) analysed during the on-treatment period from the 
time of first dose to last dose of study drug taken + 3 days.
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Statistical analysis
The primary efficacy analysis was performed on the inten-
tion to treat population (all patients who were enrolled into 
the trial and randomly assigned). All patients who took at 
least one dose of study drug (the safety population) were 
included in primary safety analysis. Sensitivity analyses 
were calculated in the per-protocol population of all ran-
domly assigned patients without any predefined major pro-
tocol deviations. Odds ratios and 95% confidence intervals 
are shown to evaluate the difference between treatment arms.
Results
In this analysis, 2199 patients were enrolled from 2014 to 
2015, from 239 centers in 19 countries in Europe and the 
United States of America: 1095 patients were randomised 
to edoxaban and 1104 to enox–warf. Among 1095 patients 
assigned to edoxaban, 1067 received allocated treatment, 
whilst among 1,104 patients assigned to enox–warf, 1082 
received allocated treatment. From 1095 patients assigned 
to edoxaban, 988 (90.2%) of patients from edoxaban group 
and 966 (87.5%) of those from enox–warf group were car-
dioverted electrically or spontaneously: 600 (27.3%) of all 
patients were VKA naïve (not having taken any OAC within 
30 days before randomisation), whilst 1599 (72.7%) of all 
patients were VKA experienced at randomisation. Of those 
undergoing cardioversion, 589 patients from the edoxaban 
group and 594 patients from the enox–warf group underwent 
TEE-guided cardioversion [9]. Baseline characteristics of 
patients are summarised in Table 1.
1 patient of 2199 (< 1%) was lost to follow-up.
The primary efficacy endpoint appeared in 11 (0.7%) of 
the VKA experienced group and in 5 (0.8%) of the VKA 
naïve group [odds ratio (OR) 0.58, 95% confidence inter-
val (CI) 0.12–2.30 in VKA experienced patients, OR 0.24, 
95% CI 0.0–2.46 in VKA naïve patients), Table 2. The 
Fig. 1  Study design for A non-TEE-guided stratum and B TEE-
guided stratum in ENSURE-AF. a Patients meeting ≥ 1 of the fol-
lowing criteria were dose-reduced to 30  mg: CrCl ≥ 15  mL/min 
and ≤ 50 mL/min; low body weight (≤ 60 kg); or concomitant use of 
P-glycoprotein inhibitors. b Patients with INR ≥ 2 at randomisation 
did not require enoxaparin. CrCl creatinine clearance, CVN cardiover-
sion, INR international normalised ratio, TEE transoesophageal echo-
cardiography
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Table 1  Baseline demographics
Data provided as mean (standard deviation) unless otherwise indicated
ACEI/ARB angiotensin converting enzyme inhibitor/angiotensin receptor blocker, AF atrial fibrillation, CAD coronary artery disease, CHA2DS2-
VASc congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, and prior stroke or transient ischaemic attack or thromboembolism, 
vascular disease, age 65–74 years, sex category; CrCl creatinine clearance, Enox–warf enoxaparin–warfarin, HAS-BLED hypertension, abnormal 
renal and liver function, stroke, bleeding history or disposition, labile INR, elderly, drugs or alcohol, HF heart failure, ICH intracranial haemor-
rhage, MI myocardial infarction, NOAC novel oral anticoagulant, PAD peripheral artery disease, TIA transient ischaemic attack, TiTR time in 
therapeutic range (calculated from the first day with 2 ≤ INR ≤ 3), TTR time in therapeutic range (calculated from day 8 of study drug), TtTR time 
to therapeutic range, VHD valvular heart disease, VKA vitamin K antagonist
a Current defined as using VKA or NOAC at randomisation or within 30 days prior to randomisation
b Rosendaal method





Edoxaban (n = 791) Enox–warf 
(n = 808)
Edoxaban (n = 304) Enox–warf 
(n = 296)
Age, years 64.3 (10.3) 64.2 (10.8) 64.6 (9.9) 64.1 (10.8) 63.5 (11.4) 64.3 (10.8)
  > 65, n (%) 509 (46.5) 530 (48.0) 374 (47.3) 383 (47.4) 135 (44.4) 147 (49.7)
Weight, kg 90.9 (18.3) 91.2 (19.0) 90.6 (18.4) 90.9 (19.0) 91.5 (18.1) 91.8 (19.0)
  ≤ 60, n (%) 21 (1.9) 33 (3.0) 17 (2.2) 21 (2.6) 4 (1.3) 12 (4.1)
Anticoagulant experienced, n (%)
 Current VKA  usera 513 (46.8) 558 (50.5) 484 (61.2) 529 (65.5) 29 (9.5) 29 (9.8)
 Current NOAC 
 usera
157 (14.3) 148 (13.4) 145 (18.3) 133 (16.5) 12 (3.9) 15 (5.1)
CrCl 94.0 (35.7) 94.1 (34.7) 92.5 (34.9) 92.9 (34.6) 97.8 (37.8) 97.5 (34.8)
TtTR (days) – 7.7 (5.1) – 7.4 (5.4) – 8.1 (4.5)
TiTR (% of time) – 70.8 (27.4) – 72.0 (26.8) – 67.4 (28.9)
TTR (% of time)b – 59.8 (30.6) – 61.8 (30.6) – 54.4 (30.1)
Medical history
 Congestive HF 476 (43.5) 484 (43.8) 365 (46.1) 376 (46.5) 111 (36.5) 108 (36.5)
 CAD 181 (16.5) 197 (17.8) 133 (16.8) 149 (18.4) 48 (15.8) 48 (16.2)
 Hypertension 850 (77.6) 864 (78.3) 637 (80.5) 633 (78.3) 213 (70.1) 231 (78.0)
 Diabetes 218 (19.9) 197 (17.8) 159 (20.1) 136 (16.8) 59 (19.4) 61 (20.6)
 PAD 40 (3.7) 54 (4.9) 29 (3.7) 43 (5.3) 11 (3.6) 11 (3.7)
 VHD 250 (22.8) 240 (21.7) 194 (24.5) 179 (22.2) 56 (18.4) 61 (20.6)
 ICH 2 (0.2) 3 (0.3) 1 (0.1) 3 (0.4) 1 (0.3) 0
 Ischaemic stroke/
TIA
68 (6.2) 66 (6.0) 54 (6.8) 50 (6.2) 14 (4.6) 16 (5.4)
 MI 69 (6.3) 78 (7.1) 51 (6.4) 56 (6.9) 18 (5.9) 22 (7.4)
 Life-threatening 
bleed
3 (0.3) 3 (0.3) 2 (0.3) 2 (0.2) 1 (0.3) 1 (0.3)
AF history, n (%)
 Paroxysmal 
(≤ 7 days)
208 (19.0) 207 (18.8) 103 (13.0) 119 (14.8) 105 (34.5) 88 (29.8)
 Persistent 
(> 7 days, < 1 yr)
887 (81.0) 890 (80.6) 688 (87.0) 683 (85.2) 199 (65.5) 207 (70.2)
CHA2DS2-VASc 
score
2.6 (1.49) 2.6 (1.40) 2.7 (1.5) 2.6 (1.4) 2.4 (1.5) 2.6 (1.4)
HAS-BLED score 0.9 (0.78) 0.9 (0.79) 0.9 (0.8) 0.9 (0.8) 0.8 (0.8) 0.8 (0.8)
Prior drug therapies
 Aspirin 192 (17.4) 221 (20.0) 105 (13.3) 130 (16.1) 87 (28.6) 91 (30.7)
 Statins 429 (39.2) 411 (37.2) 320 (40.5) 302 (37.4) 109 (35.9) 109 (36.8)
 ACEI/ARB 692 (63.2) 688 (62.3) 525 (66.4) 513 (63.5) 167 (54.9) 175 (59.1)
 Beta blocker 862 (78.7) 847 (76.7) 640 (80.9) 622 (77.0) 222 (73.0) 225 (76.0)
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composite of major and CRNM bleeding events occurred in 
18 (1.2%) of VKA experienced patients and in 9 (1.5%) of 
VKA naïve patients (OR 2.09, 95% CI 0.72–6.81 in VKA 
experienced patients, OR 0.77, 95% CI 0.15–3.60 in VKA 
naïve patients), Table 2.
Major bleeding appeared in five (0.3%) of VKA experi-
enced patients and in three (0.5%) of VKA naïve patients 
(OR 0.69, 95% CI 0.06–6.04 in VKA experienced patients, 
OR 0.48, 95% CI 0.01–9.25 in VKA naïve patients), Table 2.
Discussion
The ENSURE-AF provides the largest prospective trial 
dataset for edoxaban in terms of non-valvular AF patients 
scheduled for cardioversion. In this ancillary analysis from 
ENSURE-AF, our findings are as follows: (1) edoxaban had 
non-significantly different rates of primary efficacy and 
safety endpoint outcomes compared with enoxaparin–war-
farin, (2) VKA experienced patients had non-significantly 
different primary efficacy and safety endpoint outcomes to 
VKA naïve subjects.
Peri-cardioversion anticoagulation with VKA is associ-
ated with lower risk of stroke or thromboembolism than no 
anticoagulation [11]. Unfortunately, major bleeding events 
were not evaluated in the above-mentioned systematic 
review of observational studies.
Planned ECV at study entry was an exclusion criterion in 
phase 3 randomised trials which compared NOAC to war-
farin; however, ECV was performed in those trials during 
their course [12]. In a retrospective analysis of data from 
the randomised evaluation of long-term anticoagulation 
therapy (RE-LY), the proportion of stroke and major bleed-
ing within 30 days of cardioversion on dabigatran (150 mg 
twice daily and 110 mg twice daily) were low and similar to 
those on warfarin with or without TEE guidance [12, 13]. 
In other retrospective analysis [14], there were no differ-
ences in the incidence of stroke or systemic embolism and 
death in patients medicated with rivaroxaban and warfarin. 
Patients after cardioversion in the apixaban for reduction in 
stroke and other thromboembolic events in atrial fibrillation 
(ARISTOTLE) [15] were also evaluated retrospectively. The 
prevalence of MI, major bleeding and death was similar in 
patients treated with apixaban and warfarin. In the effective 
anticoagulation with factor Xa next generation (ENGAGE) 
AF-TIMI 48 trial [16], stroke or SEE, major bleeding or 
death were infrequent and similar in patients medicated with 
edoxaban and warfarin [17]. However, these studies are lim-
ited by its post-hoc, nonrandomized design, small cohort and 
lack of TEE data.
Explore the efficacy and safety of once-daily oral rivar-
oxaban for the prevention of cardiovascular events in 
patients with non-valvular atrial fibrillation scheduled for 
cardioversion (X-VeRT) [18] was a randomised, open-label 
prospective study of rivaroxaban in patients with AF under-
going elective cardioversion. Rivaroxaban (20 mg QD or 
15 mg QD in patients with moderate renal impairment) 
was associated with low thromboembolic and bleeding 
risks and broadly similar to risks in patients treated with 
VKA. Of note, in the group of patients, where cardioversion 
was performed within the target time range of 21–25 days 
after randomisation, only 36.3% of patients on warfarin 
Table 2  Event rates according to prior VKA experience classification and treatment
CI confidence interval, CRNM clinically relevant nonmajor, CV cardiovascular, Enox–warf enoxaparin–warfarin, MI myocardial infarction, OR 
odds ratio, SEE systemic embolic event, VKA vitamin K antagonist
a Intent to treat population, overall study period
b All treated patients, on-treatment period
Overall VKA experienced VKA naïve
Edoxaban Enox-warf Edoxaban Enox-warf Edoxaban Enox-warf
First stroke, SEE, MI, or CV  mortalitya
 N 1095 1104 791 808 304 296
 n (%) 5 (0.5) 11 (1.0) 4 (0.5) 7 (0.9) 1 (0.3) 4 (1.4)
 OR (95% CI) 0.46 (0.12, 1.43) 0.58 (0.12, 2.30) 0.24 (0.00, 2.46)
Major or CRNM bleeding  eventsb
 N 1067 1082 764 791 303 291
 n (%) 16 (1.5) 11 (1.0) 12 (1.6) 6 (0.8) 4 (1.3) 5 (1.7)
 OR (95% CI) 1.48 (0.64, 3.55) 2.09 (0.72, 6.81) 0.77 (0.15, 3.60)
Major bleeding  eventsb
 N 1067 1082 764 791 303 291
 n (%) 3 (0.3) 5 (0.5) 2 (0.3) 3 (0.4) 1 (0.3) 2 (0.7)
 OR (95% CI) 0.61 (0.09, 3.13) 0.69 (0.06, 6.04) 0.48 (0.01, 9.25)
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were cardioverted within the target time due to inadequate 
coagulation.
Another prospective trial, Eliquis evaluated in acute car-
dioversion compared to usual treatments for anticoagula-
tion in subjccts with atrial fibrillation (EMANATE) [19], 
showed low rates of stroke, systemic embolic events, death 
and bleeding events in both the apixaban and heparin/VKA-
treated patients. In this study, patients with AF were sched-
uled for cardioversion during anticoagulation with either 
apixaban or a conventional heparin/VKA regimen and anti-
coagulation lasted ≤ 48 h prior to randomisation. The main 
limitation of the study is the descriptive design, without 
hypothesis testing, and power calculations.
In our study, the primary efficacy endpoint outcomes 
were similar in VKA experienced and naïve patients.
Strengths and limitations
Our study has some limitations that should be noted. This 
trial was underpowered to present statistically significant 
differences for efficacy or safety endpoints. Moreover, the 
open-label study design may be associated with bias in 
reporting outcome. Strengths of the study are the prospective 
trial design which is the largest dataset comparing a NOAC 
(edoxaban) to warfarin for efficacy and safety in the peri-
cardioversion period. Enox–warf therapy was optimally used 
with acceptable time in therapeutic range. Management with 
edoxaban was associated with compliance of more than 99%.
Conclusions
Edoxaban had comparable efficacy and safety to optimized 
anticoagulation with enox–warf. The primary efficacy and 
safety endpoint outcomes were broadly similar between 
VKA experienced or naïve patients.
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